Sanofi’s key driver for this study was to reduce the operating costs of existing purification steps with high resin costs. Regulatory concerns were to be tested by determining product quality consistency through process transfer and scale-up. The feasibility of extended purifications at production scale was also determined by evaluating BioSMB system robustness.
To read the full case study, please download this free white paper.